Abstract
Introduction: Deep Brain Stimulation (DBS) Therapy is a neuromodulatory intervention that has shown significant potential in treating psychiatric disorders resistant to conventional treatments. Objectives: To evaluate symptom reduction in patients with resistant psychiatric disorders. Methodology: They consisted of a systematic literature review, where relevant articles were searched in academic databases. The inclusion criteria were defined to select studies that evaluated the surgical treatment of nephrotic syndrome and its strategies to control proteinuria and preserve renal function. For data collection, the following databases were used: Scientific Electronic Library Online (SCIELO), PubMed and Latin American Caribbean Literature in Health Sciences (LILACS). Various types of publications, such as scientific articles, monographs and magazines, were consulted to obtain relevant information on the topic. Results and Discussions: Results of Deep Brain Stimulation (DBS) Therapy for treatment-resistant psychiatric disorders have demonstrated a significant reduction in symptoms in a substantial proportion of patients. Clinical improvement was observed in both major depression and obsessive-compulsive disorder, indicating the therapeutic potential of DBS in these conditions. Furthermore, adverse effects were generally tolerable, highlighting the relative safety of this procedure. These findings suggest that DBS may be a valuable option for patients who do not respond to conventional treatments, although more research is needed to fully understand its mechanisms of action and optimize its clinical application. Conclusion: Deep Brain Stimulation (DBS) Therapy shows a promising approach for treating resistant psychiatric disorders such as major depression and obsessive-compulsive disorder. The results indicate a significant reduction in symptoms in many patients, highlighting DBS as a viable alternative when conventional treatments fail. However, long-term efficacy and safety require further research. DBS represents a significant advancement in Interventional Psychiatry, offering hope for patients with severe and refractory conditions.
References
ABAD, Luiz Henrique Salamoni et al. Estimulação Cerebral Profunda em Transtorno Obsessivo Compulsivo – Um Estudo de Revisão Sistemática. Brazilian Journal of health Review, [S. l.], v. 3, n. 5, p. 15389-15395, 29 out. 2020.
BARBIERI, Eduardo Luiz Cenci et al. Estimulação cerebral profunda como alternativa no tratamento da depressão maior e do transtorno obsessivo-compulsivo. Contribuciones a Las Ciencias Sociales, [S. l.], v. 16, n. 11, p. 26335-26353, 14 nov. 2023.
BARBOSA, Fernando Campos et al. Uma perspectiva da neurociência sobre a psiquiatria intervencionista. Revista GeSec, [S. l.], v. 14, n. 4, p. 4540-4554, 14 nov. 2023.
Berman J, Ambrose AJ. Prioritizing patient preferences: a practical guide for tailoring treatment choices in interventional psychiatry. J Clin Psychiatry.; v.83, n.3, p.22, 2022.
Brunoni AR, Valiengo L, Gallucci-Neto J. Interventional Psychiatry: 13 reasons why. Braz J Psychiatry.; v.44, n.6, p.565-566, 2022.
Conway CR, Sackeim HA. Interventional psychiatry: the revolution has arrived. Braz J Psychiatry ;v.44, n.6, p.570-571, 2022.
Ithman M, Sobule R, Kundert C, Campbell A, Ehrhardt E. Ketamine Infusions Administered Solely by Psychiatric Staff. Mo Med.; v.119, n.2, p.164-166, 2022.
Kokane SS, Armant RJ, Bolaños-Guzmán CA, Perrotti LI. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant. Behav Brain Res.; v.384, n.11, p.25, 2020.
Liu Y, Lin D, Wu B, Zhou W. Ketamine abuse potential and use disorder. Brain Res Bull.; v.126, n.1, p.68-73, 2016.
McIntyre RS, Rodrigues NB, Lee Y, Lipsitz O, Subramaniapillai M, Gill H, Nasri F, Majeed A, Lui LMW, Senyk O, Phan L, Carvalho IP, Siegel A, Mansur RB, Brietzke E, Kratiuk K, Arekapudi AK, Abrishami A, Chau EH, Szpejda W, Rosenblat JD. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. J Affect Disord.; v.274, n.12, p. 903-910, 2020.
Nikayin S, Taylor JJ, Ostroff RB. Advanced training in interventional psychiatry. J Neurol Sci.; v.434, n.12, p.93, 2022.
Rosenbaum SB, Gupta V, Patel P, Palacios JL. Ketamine. [Updated 2022 Nov 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan- . Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK470357/. Acesso em: 25 fev 2023.
Trapp NT, Williams NR. The Future of Training and Practice in Neuromodulation: An Interventional Psychiatry Perspective. Front Psychiatry.; v.12, n.73, p.4487, 2021.
Trapp, Williams. The Future of Training and Practice in Neuromodulation: An Interventional Psychiatry Perspective. Front Psychiatry.; v.12, n.73, 2021.
Vincent KM, Ryan M, Palmer E, Rosales JL, Lippmann S, El-Mallakh RS. Interventional psychiatry. Postgrad Med.; v.132, n.7, p.573-574, 2020.
Wilkinson ST, Sanacora G. Ketamine: a potential rapid-acting antisuicidal agent? Depress. Anxiety; v.33, n.711–717, 2016.
Williams NR, Taylor JJ, Kerns S, Short EB, Kantor EM, George MS. Interventional psychiatry: why now? J Clin Psychiatry.; v.75, n.8, p.895-7, 2014.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Salete Martens Aurélio, Núbia de Amorim Costa Hoth, Bárbara de Oliveira Baptista Savariego, Átila Castro Paiva, Aguinaldo Pereira Dias, Lucas Lisboa de Liz Sousa, Fabiola Gondim Medeiros Chaves, Isabelle de Miranda Corrêa, Leonardo Sobral Torres Bezerra, Rayane Batista Pinheiro, Eduardo Henrique Resende Rocha, Antônio Carlos da Silva Araújo Neto , Amanda Tollini de Moraes